Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Psoriasis and Diabetes Risk Examined in Cohort

J Am Acad Dermatol; ePub 2017 Nov 8; Wan, et al

Clinicians may measure body surface area (BSA) affected by psoriasis in order to target diabetes prevention efforts for patients with psoriasis, a recent study found. Researchers conducted a prospective, population-based, cohort study of 8,124 adults with psoriasis and 76,599 adults without psoriasis for approximately 4 years. They found:

  • 280 (3.44%) incident cases of diabetes in the psoriasis group and 1,867 (2.44%) incident cases of diabetes in those without psoriasis.
  • After adjusting for age, sex, and body mass index, the hazard ratios for developing incident diabetes were 1.21 (1.01-1.44), 1.01 (0.81-1.26), and 1.64 (1.23-2.18) in the ≤2BSA, 3-10%BSA, and >10%BSA groups compared to those without psoriasis, respectively.
  • Worldwide, an estimation included an additional 125,650 new diagnoses of type 2 diabetes mellitus per year in patients with psoriasis, as compared to those without.

Citation:

Wan MT, Shin DB, Hubbard RA, Noe MH, Mehta NN, Gelfand JM. Psoriasis and the risk of diabetes: A prospective population-based cohort study. [Published online ahead of print November 8, 2017]. J Am Acad Dermatol. doi:10.1016/j.jaad.2017.10.050.